cadonilimab

Cadonilimab is a first-in-class, humanized IgG1 tetrameric bispecific monoclonal antibody that targets both programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4). By binding to PD-1 and CTLA-4 on tumor-infiltrating T lymphocytes, cadonilimab blocks their interaction with respective ligands (PD-L1/PD-L2 for PD-1; B7.1/B7.2 for CTLA‑4), thereby inhibiting immunosuppressive signaling pathways and promoting the activation of tumor-specific T-cell immunity. Its Fc-null design reduces cellular phagocytosis and antibody-mediated toxicity compared to traditional combination checkpoint blockade, resulting in improved efficacy with lower toxicity. Cadonilimab has demonstrated clinical benefit across multiple solid tumors, including cervical cancer and gastric cancer, where it is approved or under regulatory review. It is being investigated in numerous other cancers as monotherapy or in combination regimens[3][5][7].

Brand names

Cadonilimab

Other names

Anti-PD1/Anti-CTLA4 bispecific antibody AK104PD-1 x CTLA-4 dual checkpoint inhibitor AK104PD1 x CTLA-4 dual checkpoint inhibitor AK104PD 1 x CTLA-4 dual checkpoint inhibitor AK104